Following the sector’s best IPO start in three years, BioPharma Dive spoke with industry insiders about what they expect to see in the months ahead.
The two pharmacy retailers will begin dispensing mifepristone in some states weeks before the start of a Supreme Court case that will decide how widely the pill can be accessed.
The rejection is the latest setback in the pharmaceutical industry’s efforts to use the courts to challenge Medicare’s new pricing powers.
Nocion will use the cash to start a mid-stage trial testing its medicine, a potential rival to a drug GSK acquired last year in a $2 billion deal.
The updated results show that responses to the drug, which is currently in late-stage testing, deepened with time, helping the company rebound from an earlier setback.
Less than two years after Bristol Myers bought Turning Point for $4.1 billion, Jean Cui and Peter Li have built a new startup that’s brought in more than $170 million in funding.
One of the investment firm’s startups will work with Gilead to expand the cancer drug’s label under the unusual arrangement, with Abingworth receiving payment if successful.
The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized cancer vaccine.
The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.
The startup, Kenai Therapeutics, has raised $82 million and will be chaired by Jeff Jonas, a new Cure partner and former CEO of Sage Therapeutics.
The infusion from unnamed private investors will bolster the company’s balance sheet days after a Sanofi-partnered ALS drug stumbled in a clinical trial.